Abstract:Objective To explore the application effect of standardized pharmaceutical care model in the whole process management of cancer pain. Methods A total of 123 patients with cancer pain who were admitted to Panzhihua Integrated Traditional Chinese and Western Medicine Hospital, Sichuan Province from March 2016 to May 2019 were selected as research objects and divided into control group (61 cases) and study group (62 cases) according to the random number table method. The control group only used drugs according to doctor’s orders. The study group was given standardized pharmaceutical care model management. After one month of intervention, the pain, quality of life and improvement situation of medication compliance in the two groups were observed. Adverse reactions during the intervention were recorded. Results The numerical rating scoring (NRS) scores of two groups were lower after one week and one month of intervention than before intervention, and the NRS scores after one month of intervention were lower than those after one week of intervention, the NRS score of the study group was lower than that of the control group one week and one month after intervention (P < 0.05). After one month of intervention, scores of emotion, sleep, daily life, relationship with others, interest in life, walking ability and daily work in two groups all decreased compared with that before intervention, and those in the study group were lower than those in the control group (P < 0.05). After one month of intervention, the scores of Chinese version eight items morisky medication adherence scale in two groups were higher than those before intervention, and the study group was higher than the control group (P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion The standardized pharmaceutical care model management for cancer pain patients can significantly improve their compliance with medication, effectively improve their clinical symptoms and quality of life, and also ensure the safety of medication for patients with high clinical application value.
钱军 杨朋 邓怀冬. 规范化药学服务模式在癌痛全程化管理中的应用效果[J]. 中国医药导报, 2020, 17(32): 148-151.
QIAN Jun YANG Peng DENG Huaidong. Application effect of standardized pharmaceutical care model in the whole process management of cancer pain. 中国医药导报, 2020, 17(32): 148-151.
[1] 衣学新,邓军吉.自拟芪黄蠲痛汤结合硫酸吗啡缓释片治疗癌性疼痛[J].国际中医中药杂志,2018,40(10):926-929.
[2] 林小燕,杨菁,赖金火,等.癌症患者疼痛治疗依从性的影响因素分析[J].中国疼痛医学杂志,2013,19(6):373-375.
[3] Zhou NB,Wang KG,Fu ZJ. Effect of morphine and a low dose of ketamine on the T cells of patients with refractory cancer painin vitro [J]. Oncol Lett,2019,18(4):4230-4236.
[4] Iizuka Y,Iizuka-Ohashi M,Kawasaki S,et al. Effectiveness of Strontium-89 for Neuropathic Pain Caused by Bone Metastases from Breast Cancer:A Case Report [J]. Kaku Igaku,2019,56(1):117-120.
[5] 徐丽.癌痛管理中规范化临床药学服务模式的建立及应用[J].临床合理用药杂志,2019,12(8):96-97.
[6] 王冬梅,修文明,孙雅宁,等.乳痈汤联合针灸对乳痈患者视觉模拟评分法评分、数字分级法评分和生命质量评价量表-36评分的影响[J].世界中医药,2019,14(4):1016-1019.
[7] 严广斌.NRS疼痛数字评价量表numerical rating scale [J].中华关节外科杂志:电子版,2014,8(3):410.
[8] 陈佳丽.神经病理性疼痛评估工具用于痛性糖尿病周围神经病变患者的评价[D].广州:南方医科大学,2015.
[9] 陈伟民.中文版8条目Morisky服药依从性量表在癌痛患者中的应用研究[J].中国医药导报,2015,10(22):45-46.
[10] 谢晨,蔡周权.癌痛规范化病房创建活动中临床药师作用探讨[J].中国药业,2019,28(4):86-88.
[11] 唐小丽,张婷,杨慧,等.四川省55所二级甲等及以上医院癌痛规范化护理的现状分析[J].中华护理杂志,2016, 51(4):424-428.
[12] 郭首兵,左拥军,角灿武,等.我院2009~2011年门诊癌痛患者就诊情况调查分析[J].中国实用医药,2012,7(35):170-172.
[13] 史秀梅,胡永领,梁艳丽等.肝功能损害患者临床药学服务模式的探索及效果评价[J].中国药物警戒,2018, 15(5):286-290.
[14] Rhew K,Han N,Cho KT,et al. Prioritization of diseases for the development of a pharmaceutical care service model in South Korea using the analytic hierarchy process [J]. Int J Clin Pharmacol Ther,2017,55(11):866-874.
[15] 陈璐,陈岷,童荣生,等.合作药物治疗管理模式在癌痛规范化治疗中的应用[J].中国药师,2017,20(1):127-130.
[16] Lap?觔o LV,da Silva MM,Gregório J. Implementing an online pharmaceutical service using design science research [J]. BMC Med Inform Decis Mak,2017,17(1):31.
[17] 刘宇,邱峰,张涛,等.癌痛管理中规范化临床药学服务模式的建立及应用[J].中国医院药学杂志,2016,36(2):126-129.
[18] 关世奎,彭晋.新形势下医院药学模式转变与发展[J].解放军医院管理杂志,2014,(5):406-407,414.
[19] Ducournau P,Irl C,Tatt I,et al. Timely,consistent,transparent assessment of market access evidence: implementing tools based on the HTA Core Model? in a pharmaceutical company [J]. Int J Technol Assess Health Care,2019,35(1):10-16.
[20] 谷铁波,康敏,袁微,等.规范化药学服务模式在癌痛全程化管理中的应用研究[J].中南药学,2019,17(5):752-755.